Allergan PLC tried to put the most positive spin on it, but top-line two-year data from a Phase IIb study of its lead NASH candidate cenicriviroc has analysts wondering what’s the drug’s benefit will be if any. With Allergan revealing Sept. 22 that after two years of treatment, cenicriviroc (CVC) showed no meaningful difference compared to placebo in reducing fibrosis score in NASH patients, Credit Suisse went as far as removing potential revenue for the drug from its modeling.
Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit
A year after acquiring cenicriviroc in its Tobira buyout, Allergan says two-year data from a Phase IIb trial supports continued development, but analysts think the drug’s prospects have dimmed.
More from Clinical Trials
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.